LPL Financial
DNLI icon

LPL Financial’s Denali Therapeutics DNLI Stock Holding History

LPL Financial’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$357K Buy
13,868
+1,594
+13% +$32.8K ﹤0.01% 5313
2026
Q1 		$236K Buy
12,274
+1,770
+17% +$35.2K ﹤0.01% 5376
2025
Q4 		$173K Sell
10,504
-144
-1% -$2.43K ﹤0.01% 5486
2025
Q3 		$155K Buy
+10,648
New +$153K ﹤0.01% 5419
2024
Q2 		– Sell
-34,085
Closed -$699K – 5047
2024
Q1 		$699K Buy
+34,085
New +$641K ﹤0.01% 3489
2021
Q3 		– Sell
-3,266
Closed -$256K – 4348
2021
Q2 		$256K Buy
+3,266
New +$202K ﹤0.01% 3713
2021
Q1 		– Sell
-3,519
Closed -$295K – 4098
2020
Q4 		$295K Buy
+3,519
New +$213K ﹤0.01% 3210

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

LPL Financial's DNLI Position: Q2 2026 in Review

LPL Financial increased its Denali Therapeutics (DNLI) stake by 13% in Q2 2026, buying an estimated $32.8K and bringing the position to 13,868 shares worth $357K. The position accounts for ﹤0.01% of the portfolio, ranked #5313.

LPL Financial first reported a position in DNLI in Q4 2020 and has held it in 7 quarters since. The position peaked at $699K in Q1 2024. 112 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • LPL Financial held 13,868 shares of Denali Therapeutics worth $357K as of Q2 2026.
  • LPL Financial bought 1,594 Denali Therapeutics shares in Q2 2026, an estimated $32.8K.
  • Denali Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #5313 holding.
  • LPL Financial first reported a position in Denali Therapeutics in Q4 2020 and has held it in 7 quarters since.
  • LPL Financial's Denali Therapeutics position peaked at $699K in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.